drugset / Trial / NCT01785836

An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris

NCT01785836

Phase 1 Withdrawn Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety, tolerability, and efficacy of dapsone in subjects with acne vulgaris following 12 weeks of treatment.

Timeline

Start
2013-03
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapsone Small molecule 5 % Topical

Indications